About Diasome Pharmaceuticals
Diasome Pharmaceuticals develops hepatocyte directed vesicle technology, an insulin additive, to lessen the instances of high and low blood sugar levels in people with diabetes to improve disease management and quality of life. The company was founded in 2004 and is based in Cleveland, Ohio.
Missing: Diasome Pharmaceuticals's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Diasome Pharmaceuticals's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Research containing Diasome Pharmaceuticals
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Diasome Pharmaceuticals in 1 CB Insights research brief, most recently on Oct 28, 2022.
Expert Collections containing Diasome Pharmaceuticals
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Diasome Pharmaceuticals is included in 2 Expert Collections, including Biopharma Tech.
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Latest Diasome Pharmaceuticals News
Oct 14, 2022
Diasome Pharmaceuticals, the Cleveland startup that is developing a helper drug to treat diabetes, topped the list.
Diasome Pharmaceuticals Web Traffic
Diasome Pharmaceuticals Rank
Diasome Pharmaceuticals Frequently Asked Questions (FAQ)
When was Diasome Pharmaceuticals founded?
Diasome Pharmaceuticals was founded in 2004.
Where is Diasome Pharmaceuticals's headquarters?
Diasome Pharmaceuticals's headquarters is located at 10000 Cedar Avenue, Cleveland.
What is Diasome Pharmaceuticals's latest funding round?
Diasome Pharmaceuticals's latest funding round is Unattributed.
How much did Diasome Pharmaceuticals raise?
Diasome Pharmaceuticals raised a total of $80.79M.
Who are the investors of Diasome Pharmaceuticals?
Investors of Diasome Pharmaceuticals include Flare Capital Partners, JDRF T1D Fund, McDonald Partners, Medicxi Ventures, Black Beret Life Sciences and 5 more.
Who are Diasome Pharmaceuticals's competitors?
Competitors of Diasome Pharmaceuticals include Adastra Pharmaceuticals, Intarcia Therapeutics, Rigel Pharmaceuticals, Amylin Pharmaceuticals, Tioga Pharmaceuticals and 12 more.
Compare Diasome Pharmaceuticals to Competitors
Xenome focuses on the discovery and development of peptide pharmaceuticals based on libraries of venom and related peptides.
Alinea Pharmaceuticals, Inc. offers pharmaceuticals for diabetes and related metabolic disorders
Hormos Medical, A Subsidiary Of Quatrx Pharmaceuticals, Focuses On Developing Therapies For Endocrine, Metabolic And Cardiovascular Diseases.
Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.
Actinobac Biomed is a biopharmaceutical company developing therapeutics for multiple indications, including blood cancers, autoimmune/inflammatory diseases, and HIV. Its drug candidates are based upon Leukothera (LtxA), a natural protein that targets and eliminates white blood cells (WBCs) involved in the mechanism of many diseases. Products based upon Leukothera are being developed by Actinobac for the treatment of leukemia/lymphoma, dry eye, and psoriasis.
Inagen was formed in 2007 to develop therapies for viral diseases. The company's primary candidate is treatment for Cytomegalovirus (CMV). There is a great unmet need for effective treatment to eradicate this serious disease.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.